CN108836971B - Ws6对小梁网细胞肌动蛋白形成的影响 - Google Patents

Ws6对小梁网细胞肌动蛋白形成的影响 Download PDF

Info

Publication number
CN108836971B
CN108836971B CN201810932051.6A CN201810932051A CN108836971B CN 108836971 B CN108836971 B CN 108836971B CN 201810932051 A CN201810932051 A CN 201810932051A CN 108836971 B CN108836971 B CN 108836971B
Authority
CN
China
Prior art keywords
trabecular meshwork
actin
formation
meshwork cells
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810932051.6A
Other languages
English (en)
Other versions
CN108836971A (zh
Inventor
张从晓
王克威
朱玮
于红霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao University
Original Assignee
Qingdao University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao University filed Critical Qingdao University
Priority to CN201810932051.6A priority Critical patent/CN108836971B/zh
Publication of CN108836971A publication Critical patent/CN108836971A/zh
Application granted granted Critical
Publication of CN108836971B publication Critical patent/CN108836971B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明公开了WS6对小梁网细胞肌动蛋白形成的影响。WS6为促胰岛β细胞增殖活性化合物。WS6对小梁网细胞的细胞毒性。WS6抑制小梁网细胞肌动蛋白的形成。本发明的有益效果是揭示了WS6能够显著抑制TRPV4激动剂GSK101引起的小梁网细胞肌动蛋白的形成。这有助于降低眼压，对眼压升高引起的青光眼有潜在的治疗意义。

Description

WS6对小梁网细胞肌动蛋白形成的影响
技术领域
本发明属于医学技术领域，涉及WS6(促胰岛细胞增殖药物)对小梁网细胞肌动蛋白形成的影响。
背景技术
青光眼(Glaucomas)是一种视网膜神经节细胞退变引起的一种视神经疾病，能够导致视盘凹陷、视野缺损，最终可以导致失明。
研究表明，高眼压是青光眼的重要治病因素。每降低1mm Hg眼压，能减少大约10％青光眼进程。高眼压主要由眼前节房水循环失衡而导致。房水产生于睫状体，通过位于虹膜与晶状体之间的狭小缝隙而进入眼前节的房水循环中，随后通过房水外排途径排出眼睛。房水外排的阻力主要来自于小梁网外排途径，原发性开角型青光眼患者的房水外排途径通常会出现异常，从而导致高眼压的产生。
小梁网是定位于角膜基部毗邻睫状体的筛板状组织，其正常功能的维持对房水循环的平衡以及眼内压的维持具有至关重要的作用。青光眼眼压升高80-90％的阻力来自小梁网细胞房水外排的不畅，而这与肌动蛋白的增加有密切关系。研究表明，TRPV4离子通道能够调节钙离子平衡、肌动蛋白形成、细胞骨架重构、房水外排、降低眼压。
发明内容
本发明的目的在于提供WS6对小梁网细胞肌动蛋白形成的影响。
本发明所采用的技术方案是WS6对小梁网细胞肌动蛋白形成的影响。
进一步，WS6为促胰岛β细胞增殖活性化合物。
进一步，WS6对小梁网细胞的细胞毒性。
进一步，WS6抑制小梁网细胞肌动蛋白的形成。
本发明的有益效果是揭示了WS6能够显著抑制TRPV4激动剂GSK101引起的小梁网细胞肌动蛋白的形成。这有助于降低眼压，对眼压升高引起的青光眼有潜在的治疗意义。
附图说明
图1是WS6作用于小梁网细胞后的激光共聚焦图像
图2是WS6作用于小梁网细胞后对肌动蛋白形成的抑制作用统计图
具体实施方式
下面结合具体实施方式对本发明进行详细说明。
1WS6对小梁网细胞的细胞毒性
首先，我们选取了10μM、100μM、200μM、300μM等4个梯度浓度的WS6进行其对小梁网细胞的毒性试验。结果表明，经过24h后，随着WS6浓度的增加，小梁网细胞死亡率逐渐增加，到200μM时，死亡率达到了约50％。因此，我们首先选取了10μM的WS6进行药效学试验。
2WS6抑制小梁网细胞肌动蛋白的形成
我们通过鬼笔环肽特异荧光染色技术与激光共聚焦技术，研究了WS6对小梁网细胞肌动蛋白形成的抑制作用。如图1、图2所示结果显示，TRPV4激动剂GSK101能够显著增强小梁网细胞激动蛋白的荧光强度，而加入10uM WS6后小梁网细胞激动蛋白的荧光强度显著降低。
本发明研究利用鬼笔环肽特异荧光染色技术与激光共聚焦技术，研究了WS6对小梁网细胞肌动蛋白形成的抑制作用。结果表明，10μM WS6能够显著抑制TRPV4激动剂GSK101引起的小梁网细胞肌动蛋白的形成。这有助于降低眼压，对眼压升高引起的青光眼有潜在的治疗意义。
以上所述仅是对本发明的较佳实施方式而已，并非对本发明作任何形式上的限制，凡是依据本发明的技术实质对以上实施方式所做的任何简单修改，等同变化与修饰，均属于本发明技术方案的范围内。

Claims (4)

1.WS6在制备用于肌动蛋白增加导致的青光眼治疗药物中的用途。
2.如权利要求1所述的用途，其特征在于：所述WS6为促胰岛β细胞增殖活性化合物。
3.如权利要求1所述的用途，其特征在于：所述WS6对小梁网细胞具有细胞毒性。
4.如权利要求3所述的用途，所述WS6对小梁网细胞的毒性耐受浓度为10μM。
CN201810932051.6A 2018-08-16 2018-08-16 Ws6对小梁网细胞肌动蛋白形成的影响 Active CN108836971B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810932051.6A CN108836971B (zh) 2018-08-16 2018-08-16 Ws6对小梁网细胞肌动蛋白形成的影响

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810932051.6A CN108836971B (zh) 2018-08-16 2018-08-16 Ws6对小梁网细胞肌动蛋白形成的影响

Publications (2)

Publication Number Publication Date
CN108836971A CN108836971A (zh) 2018-11-20
CN108836971B true CN108836971B (zh) 2020-10-30

Family

ID=64189391

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810932051.6A Active CN108836971B (zh) 2018-08-16 2018-08-16 Ws6对小梁网细胞肌动蛋白形成的影响

Country Status (1)

Country Link
CN (1) CN108836971B (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194808A1 (en) * 2005-01-14 2006-08-31 Chronorx Llc, An Alaska Limited Liability Company Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate
CN102083443A (zh) * 2008-04-09 2011-06-01 北卡罗来纳大学查珀尔希尔分校 调节肌动蛋白细胞骨架重排和细胞间间隙形成的方法
CN102438647A (zh) * 2009-05-12 2012-05-02 生物相容英国有限公司 使用编码和分泌神经保护因子和/或抗血管形成因子的包囊细胞治疗眼疾病
WO2013152109A1 (en) * 2012-04-04 2013-10-10 Dana-Farber Cancer Institute, Inc. Trpv4 antagonist and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194808A1 (en) * 2005-01-14 2006-08-31 Chronorx Llc, An Alaska Limited Liability Company Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate
CN102083443A (zh) * 2008-04-09 2011-06-01 北卡罗来纳大学查珀尔希尔分校 调节肌动蛋白细胞骨架重排和细胞间间隙形成的方法
CN102438647A (zh) * 2009-05-12 2012-05-02 生物相容英国有限公司 使用编码和分泌神经保护因子和/或抗血管形成因子的包囊细胞治疗眼疾病
WO2013152109A1 (en) * 2012-04-04 2013-10-10 Dana-Farber Cancer Institute, Inc. Trpv4 antagonist and methods of use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Jonathan G. Swoboda et al.Small Molecule Mediated Proliferation of Primary Retinal Pigment.《ACS Chem. Biol》.2013,(第8期),第1407-1411页. *
L. Marko et al.Renoprotection: focus on TRPV1, TRPV4, TRPC6 and TRPM2.《Acta Physiologica》.2017,第591-614页. *
Weijun Shen et al.Small-Molecule Inducer of β Cell Proliferation Identified by High Throughput Screening.《Journal of the American Chemical Society》.2013,第135卷(第5期),第1669-1672页. *
Xin Ma et al.Functional Role of TRPV4-KCa2.3 Signaling in Vascular Endothelial Cells in Normal and Streptozotocin-Induced Diabetic Rats.《Hypertension》.2013,第62卷(第1期),第134-139页. *
钟丽春 等.转化生长因子-β1 对培养的人眼小梁细胞微丝肌动蛋白的影响.《中华眼科杂志》.1999,第35卷(第3期),第186-189页. *

Also Published As

Publication number Publication date
CN108836971A (zh) 2018-11-20

Similar Documents

Publication Publication Date Title
Tanihara et al. Intra‐ocular pressure‐lowering effects of a Rho kinase inhibitor, ripasudil (K‐115), over 24 hours in primary open‐angle glaucoma and ocular hypertension: a randomized, open‐label, crossover study
Gordon et al. Late effects of radiation on the eye and ocular adnexa
Ehinger Adrenergic nerves in the avian eye and ciliary ganglion
Glybina et al. Intravitreous delivery of the corticosteroid fluocinolone acetonide attenuates retinal degeneration in S334ter-4 rats
Oatts et al. In vitro and in vivo comparison of two suprachoroidal shunts
Črnej et al. Effect of penetrating keratoplasty and keratoprosthesis implantation on the posterior segment of the eye
AU2014229371B2 (en) Compositions for use in treating eye disorders using dipyridamole
Pitha et al. Sustained Dorzolamide Release Prevents Axonal and Retinal Ganglion Cell Loss in a Rat Model of IOP–Glaucoma
Park et al. Effects of nuclear factor-κB small interfering RNA on posterior capsule opacification
CN108836971B (zh) Ws6对小梁网细胞肌动蛋白形成的影响
Vallabh et al. Corneal endothelial cell loss in glaucoma and glaucoma surgery and the utility of management with descemet membrane endothelial keratoplasty (DMEK)
Colitz et al. Cetacean and pinniped ophthalmology
Liu et al. Tissue responses and wound healing following laser scleral microporation for presbyopia therapy
US9254289B2 (en) Methods for treating eye disorders using dipyridamole
Kumar et al. Ocular angiostrongyliasis: removal of a live nematode from the anterior chamber
Rahman et al. Recurrence rate of pterygium following surgical excision with intraoperative versus postoperative mitomycin-C
Spaide et al. Cystoid macular edema after cataract surgery
Duan et al. Short-term adaptation in the peripheral auditory system is related to the AMPA receptor
KR102068697B1 (ko) 염증성 안구표면질환의 예방 또는 치료용 조성물
RU2585400C2 (ru) Лекарственная форма на основе бутиламиногидроксипропоксифеноксиметил метилоксадиазола
Zou et al. New ideas for medical therapy of glaucoma in the future
Meier-Gibbons et al. Aqueous Humor Dynamics and Its Influence on Glaucoma
Brooks Hypertensive iridocyclitis and glaucoma of horses
Tripathy et al. Corneal changes in diabetes mellitus
Nowak et al. Protective effect on visual functions of long-term use of trimetazidine in treatment of primary open angle glaucoma and degenerative myopia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder

Address after: 266100 Hongkong East Road, Laoshan District, Qingdao, Shandong Province, No. 7

Patentee after: QINGDAO University

Address before: 266071 No. 308, Ningxia Road, Qingdao, Shandong

Patentee before: QINGDAO University

CP02 Change in the address of a patent holder